BRY812 for advanced gynecological cancers
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new drug, BRY812, in women with advanced ovarian, endometrial, or ovarian clear cell cancer whose tumors have a specific marker called LIV-1. The goal is to see if it can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- Your cancer must have a protein called LIV-1, which will be checked in a lab.
- You have advanced ovarian cancer (high-grade serous type) and have had 1 to 3 prior treatments, OR you have advanced endometrial cancer (any type except sarcoma) and have had up to 3 prior treatments including platinum chemo and an immunotherapy drug, OR you have ovarian clear cell cancer and have had 1 to 3 prior treatments.
- Your cancer has gotten worse after your most recent treatment.
- You have at least one tumor that can be measured on a scan.
- You are in good enough health for daily activities (ECOG 0 or 1) and your organs are working well (kidney, liver, blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SKB518, either alone or with other treatments, for people with advanced gynecologic cancers (ovarian, cervical, or endometrial) who have already had some treatment. It aims to see if the drug helps shrink or control the cancer.
This trial tests an experimental drug called BRY812 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective against a protein called LIV-1 found on some cancer cells.
This trial tests different doses of a new drug (BI 3820768) in people with advanced solid tumors, specifically germ cell tumors, endometrial cancer, or ovarian cancer. The goal is to see if the drug is safe and how well it works.
This Phase 1/2 study tests BL-B01D1 in people with recurrent or metastatic gynecologic cancers (such as ovarian, uterine, or cervical cancer) when standard treatments have failed or aren’t options. It focuses on how well the drug works and whether it can be given safely.
This trial tests a new targeted drug (LY4175408) for people with certain advanced solid tumors (lung, endometrial, or triple negative breast cancer) who have already tried standard treatments. The goal is to see if the drug is safe and effective.
This trial tests a new drug called BL-B01D1, alone or combined with another drug (SI-B003), for people with cervical or other gynecologic cancers that have spread or come back after standard treatments. The goal is to see if this treatment can help when other options have stopped working.
Hear when a new Advanced Gynecological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.